Australia

Imugene CEO Leslie Chong backs immuno-oncology strategy with further share purchase

Imugene Ltd (ASX:IMU) managing director and chief executive officer Leslie Chong has further demonstrated confidence in the companys immuno-oncology strategy by purchasing more shares.

Chong purchased 475,240 at 1.8 cents per share on March 16 and now holds 4,387,124 shares and 77,098,765 options.

PD1-Vaxx study


The companys PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.

The drug will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.

The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

HER-Vaxx trial


The HER-Vaxx trial is targeting HER-2 positive gastric cancer.

To date, the PhaseRead More – Source